Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

KT-579 demonstrated activity comparable or superior to approved and clinically active therapies in preclinical IBD models